Neurohypophyseal Diabetes Insipidus Overview
Learn About Neurohypophyseal Diabetes Insipidus
Arginine vasopressin deficiency (previously called neurohypophyseal diabetes insipidus) is a disorder of water balance. The body normally balances fluid intake by releasing fluid in urine. However, people with arginine vasopressin deficiency produce an excessive amount of urine (polyuria), which depletes the amount of water in the body. This water loss also leads to excessive thirst (polydipsia).
The familial form of arginine vasopressin deficiency is caused by variants (also called mutations) in the AVP gene. This gene provides instructions for making a hormone called arginine vasopressin (AVP), which is sometimes also called antidiuretic hormone (ADH). This hormone, which is produced and stored in the brain, helps control the body's water balance.
Arginine vasopressin deficiency occurs in approximately 1 in 25,000 individuals. The acquired form is much more common than the familial form.
Familial arginine vasopressin deficiency is almost always inherited in an autosomal dominant pattern, which means that one copy of the altered AVP gene in each cell is sufficient to cause the disorder.
Mirjam Crain-Christ practices in Basel, Switzerland. Crain-Christ is rated as an Elite expert by MediFind in the treatment of Neurohypophyseal Diabetes Insipidus. Their top areas of expertise are Diabetes Insipidus (DI), Neurohypophyseal Diabetes Insipidus, Low Sodium Level, Osmotic Diuresis, and Hormone Replacement Therapy (HRT).
Cihan Atila practices in Basel, Switzerland. Atila is rated as an Elite expert by MediFind in the treatment of Neurohypophyseal Diabetes Insipidus. Their top areas of expertise are Neurohypophyseal Diabetes Insipidus, Diabetes Insipidus (DI), Osmotic Diuresis, and Low Sodium Level.
Julie Refardt practices in Basel, Switzerland. Ms. Refardt is rated as an Elite expert by MediFind in the treatment of Neurohypophyseal Diabetes Insipidus. Her top areas of expertise are Diabetes Insipidus (DI), Osmotic Diuresis, Neurohypophyseal Diabetes Insipidus, and Low Sodium Level.
Summary: The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and emp...
Summary: This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose intranasal oxytocin (6 IU and 24 IU) vs. placebo in adult men and women (aged 18 years and above) with arginine-vasopressin deficiency to evaluate the effect of oxytocin on anxiety, depression, and socioemotional functioning (Part A), with an optional randomized, double-blind, placebo-controlled 2-week repe...
Published Date: July 19, 2024
Published By: National Institutes of Health